IMVT
Immunovant, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+7/100
Last price
32.11
▼ 1.14 (3.43%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
33.48
Prev close
33.25
Day high
33.51
Day low
31.36
Volume
1.67M
Market cap
$6.63B
P/E (TTM)
—
52W range
16.04 – 45.42
Day trading desk
Gap from prior close
+0.69%
Prior close 33.25
VWAP
32.04
+0.23% from price
Relative volume
2.35×
Unusually busy
Session range
8.42%
31.36 – 34.00
Position in range
28%
Near session low
ATR (14D)
1.42
4.41% of price
Prior day high
33.99
PDH
Prior day low
32.95
PDL
Bid / ask spread
—
Quote not published
Session volume
2.86M
Avg 1.22M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.03%
-6.0%
1M
-18.19%
-19.3%
3M
-20.34%
-24.9%
6M
+30.48%
+12.3%
YTD
+26.32%
+12.1%
1Y
+90.00%
+73.6%
3Y
-16.36%
-98.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on IMVT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+747.25K
Net buying
Buy transactions
21
1.15M shares
Sell transactions
26
406.31K shares
Net transactions
+47
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
115.70M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | VENKER ERIC Chief Executive Officer |
SELL | 3.51K | $119.59K | Direct |
| Oct 1, 26 | VENKER ERIC Chief Executive Officer |
CONVERSION | 92.19K | $1.33M | Direct |
| Aug 28, 26 | PANDE ATUL Director |
SELL | 1.50K | $64.91K | Direct |
| Aug 28, 26 | PANDE ATUL Director |
CONVERSION | 1.50K | $12.64K | Direct |
| Aug 20, 26 | GLORIA MELANIE Chief Operating Officer |
SELL | 3.06K | $134.95K | Direct |
| Jul 24, 26 | PANDE ATUL Director |
SELL | 1.50K | $59.70K | Direct |
| Jul 24, 26 | PANDE ATUL Director |
CONVERSION | 1.50K | $12.64K | Direct |
| Jul 23, 26 | GIRÃO TIAGO M Chief Financial Officer |
SELL | 6.80K | $263.01K | Direct |
| Jul 23, 26 | STOUT JAY S Chief Technology Officer |
SELL | 2.86K | $110.54K | Direct |
| Jul 8, 26 | GLORIA MELANIE Chief Operating Officer |
SELL | 2.04K | $80.53K | Direct |
| Jul 8, 26 | VAN TUYL CHRISTOPHER Officer |
SELL | 1.21K | $47.70K | Direct |
| Jul 8, 26 | STOUT JAY S Chief Technology Officer |
SELL | 3.49K | $137.93K | Direct |
| Jul 2, 26 | VENKER ERIC Chief Executive Officer |
SELL | 3.09K | $118.98K | Direct |
| Jul 1, 26 | VENKER ERIC Chief Executive Officer |
CONVERSION | 92.19K | $1.33M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARNETT EVA RENEE |
Chief Financial Officer | 396.77K | Sale |
GEFFNER MICHAEL |
Officer | 217.96K | Sale |
GIRÃO TIAGO M |
Chief Financial Officer | 240.80K | Sale |
GLORIA MELANIE |
Chief Operating Officer | 219.30K | Sale |
LEVINE MARK S |
Officer | 319.23K | Sale |
MACIAS WILLIAM L |
Officer | 357.35K | Sale |
ROIVANT SCIENCES LTD. |
Director and Beneficial Owner of more than 10% of a Class of Security | 113.32M | Purchase |
SALZMANN PETER |
Chief Executive Officer | 1.18M | Sale |
TORTI FRANK M |
Director | 1.01M | Stock Award(Grant) |
VENKER ERIC |
Chief Executive Officer | 257.07K | Sale |
Fundamentals
Market cap$6.63B
Enterprise value$5.83B
Revenue (TTM)—
Gross profit—
EBITDA$-565.61M
Net income$-538.22M
EPS (TTM)$-2.73
Free cash flow$-238.70M
Total cash$797.80M
Total debt$0
Book value / share$3.57
Shares outstanding206.55M
Float91.79M
Short % of float18.57%
Dividend yield0.00%
Beta (5Y)0.84
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.68
PEG ratio—
Price / sales—
Price / book9.01
EV / revenue—
EV / EBITDA-10.32
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-80.10%
Return on assets-46.73%
Debt / equity—
Current ratio7.27
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $456.66M | $360.92M | $212.93M | $160.26M | +26.5% |
| Selling, general & admin | $76.24M | $77.23M | $57.28M | $48.02M | -1.3% |
| Total operating expense | $532.90M | $438.15M | $270.21M | $208.28M | +21.6% |
| Operating income | -$532.90M | -$438.15M | -$270.21M | -$208.28M | -21.6% |
| Net interest income | $25.33M | $24.73M | $24.95M | $7.58M | +2.4% |
| Pre-tax income | -$505.39M | -$412.95M | -$258.77M | -$210.95M | -22.4% |
| Tax provision | $215.00K | $891.00K | $567.00K | $9.00K | -75.9% |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -22.2% |
| Net income to common | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -22.2% |
| Basic EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.5% |
| Diluted EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.5% |
| EBIT | -$532.90M | -$438.15M | -$270.21M | -$208.28M | -21.6% |
| EBITDA | -$532.49M | -$437.77M | -$269.98M | -$208.08M | -21.6% |
| Basic shares | 182.42M | 151.57M | 138.10M | 123.08M | +20.4% |
| Diluted shares | 182.42M | 151.57M | 138.10M | 123.08M | +20.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $902.11M | $713.97M | $635.37M | $376.53M | +26.4% |
| Cash & short-term investments | $902.11M | $713.97M | $635.37M | $376.53M | +26.4% |
| Accounts receivable | $1.13M | $2.08M | $5.34M | $700.00K | -45.6% |
| Total current assets | $948.82M | $767.66M | $665.77M | $404.33M | +23.6% |
| Property, plant & equipment | $515.00K | $942.00K | $595.00K | $1.50M | -45.3% |
| Total assets | $957.01M | $776.22M | $666.37M | $405.84M | +23.3% |
| Total current liabilities | $104.42M | $68.78M | $48.61M | $43.30M | +51.8% |
| Total debt | $72.00K | $98.00K | $138.00K | $1.22M | -26.5% |
| Total liabilities | $104.42M | $68.78M | $48.61M | $43.34M | +51.8% |
| Retained earnings | -$1.75B | -$1.24B | -$825.68M | -$566.35M | -40.8% |
| Shareholder equity | $852.59M | $707.45M | $617.76M | $362.49M | +20.5% |
| Working capital | $844.40M | $698.89M | $617.16M | $361.04M | +20.8% |
| Net tangible assets | $852.59M | $707.45M | $617.76M | $362.49M | +20.5% |
| Shares issued | 203.94M | 170.11M | 145.58M | 130.33M | +19.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -22.2% |
| Depreciation & amortisation | $409.00K | $377.00K | $231.00K | $193.00K | +8.5% |
| Stock-based compensation | $55.72M | $49.49M | $41.12M | $32.30M | +12.6% |
| Change in working capital | $42.06M | -$12.03M | $2.63M | -$10.85M | +449.6% |
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -8.4% |
| Capital expenditure | -$8.00K | -$759.00K | -$360.00K | -$197.00K | +98.9% |
| Investing cash flow | -$8.00K | -$759.00K | -$360.00K | -$197.00K | +98.9% |
| Financing cash flow | $595.76M | $454.49M | $472.43M | $70.89M | +31.1% |
| Free cash flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -8.1% |
| End cash position | $902.11M | $713.97M | $635.37M | $376.53M | +26.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $142.63M | $142.29M | $98.92M | $114.25M | $101.20M | +0.2% |
| Selling, general & admin | $17.69M | $17.27M | $15.44M | $17.51M | $26.02M | +2.5% |
| Total operating expense | $160.32M | $159.55M | $114.36M | $131.76M | $127.22M | +0.5% |
| Operating income | -$160.32M | -$159.55M | -$114.36M | -$131.76M | -$127.22M | -0.5% |
| Net interest income | $7.09M | $8.06M | $5.33M | $5.60M | $6.34M | -11.9% |
| Pre-tax income | -$153.22M | -$150.70M | -$109.08M | -$125.91M | -$119.70M | -1.7% |
| Tax provision | $0 | -$2.84M | $1.55M | $594.00K | $913.00K | +100.0% |
| Net income | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | -3.6% |
| Net income to common | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | -3.6% |
| Basic EPS | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -2.7% |
| Diluted EPS | -0.75 | -0.73 | -0.61 | -0.73 | -0.71 | -2.7% |
| EBIT | -$160.32M | -$159.55M | -$114.36M | -$131.76M | -$127.22M | -0.5% |
| EBITDA | -$160.23M | -$159.46M | -$114.26M | -$131.66M | -$127.12M | -0.5% |
| Basic shares | 205.55M | 203.71M | 181.51M | 173.64M | 170.87M | +0.9% |
| Diluted shares | 205.55M | 203.71M | 181.51M | 173.64M | 170.87M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | — | -11.6% |
| Cash & short-term investments | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | — | -11.6% |
| Accounts receivable | $697.00K | $1.13M | $1.64M | $1.97M | $1.94M | — | -38.5% |
| Total current assets | $851.18M | $948.82M | $1.04B | $573.55M | $651.76M | — | -10.3% |
| Property, plant & equipment | $351.00K | $515.00K | $531.00K | $632.00K | $737.00K | — | -31.8% |
| Total assets | $852.49M | $957.01M | $1.05B | $582.96M | $661.44M | — | -10.9% |
| Total current liabilities | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | — | +12.1% |
| Total debt | — | $72.00K | — | — | — | $98.00K | — |
| Total liabilities | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | — | +12.1% |
| Retained earnings | -$1.90B | -$1.75B | -$1.60B | -$1.49B | -$1.36B | — | -8.8% |
| Shareholder equity | $735.39M | $852.59M | $986.13M | $519.71M | $608.54M | — | -13.7% |
| Working capital | $734.08M | $844.40M | $976.68M | $510.29M | $598.86M | — | -13.1% |
| Net tangible assets | $735.39M | $852.59M | $986.13M | $519.71M | $608.54M | — | -13.7% |
| Shares issued | 206.26M | 203.94M | 203.32M | 174.53M | 171.07M | — | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | — | -3.6% |
| Depreciation & amortisation | $92.00K | $96.00K | $101.00K | $105.00K | $107.00K | — | -4.2% |
| Stock-based compensation | $13.77M | $11.14M | $12.71M | $13.36M | $18.51M | — | +23.6% |
| Change in working capital | $14.93M | $41.53M | $5.47M | $10.50M | -$15.44M | — | -64.1% |
| Operating cash flow | -$124.41M | -$95.06M | -$92.33M | -$102.52M | -$117.41M | — | -30.9% |
| Capital expenditure | — | — | — | — | — | -$201.00K | — |
| Investing cash flow | — | -$8.00K | $0 | $0 | $0 | -$201.00K | — |
| Financing cash flow | $20.10M | $3.64M | $564.60M | $24.59M | $2.92M | — | +452.1% |
| Free cash flow | -$124.41M | -$95.07M | -$92.33M | -$102.52M | -$117.41M | — | -30.9% |
| End cash position | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | — | -11.6% |
Options analytics
Put / call volume
0.23
Call-heavy session
Put / call open interest
0.08
Positioning, not flow
Max pain
28.00
-12.8% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
471
Contracts, this expiry
Put volume
106
Contracts, this expiry
Heaviest call OI
28.00
301 contracts
Heaviest put OI
49.00
22 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.61 | -0.68 | -10.5% |
| Mar 2026 | -0.63 | -0.67 | -7.5% |
| Dec 2025 | -0.69 | -0.54 | +22.4% |
| Sep 2025 | -0.73 | -0.65 | +10.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.72 | 3 | $0 | 0.0% |
| Next quarter | -0.67 | 3 | $0 | 0.0% |
| Current year | -2.84 | 5 | $0 | 0.0% |
| Next year | -2.75 | 5 | $36.81M | 0.0% |
Analyst targets & ownership
Mean target$48.88
High target$66.00
Low target$30.00
Implied upside52.21%
Analyst count16
ConsensusBUY
Strong buy / Buy2 / 11
Hold4
Sell / Strong sell0 / 0
Held by insiders56.02%
Held by institutions53.95%
Institutions holding313
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
33.52
-4.21% from price
SMA 20
35.46
-9.44% from price
SMA 50
38.89
-17.42% from price
SMA 100
37.26
-13.82% from price
SMA 200
31.80
+0.98% from price
EMA 12
34.18
-6.05% from price
EMA 26
36.01
-10.84% from price
EMA 50
37.14
-13.53% from price
RSI (14)
23.4
Oversold
MACD (12,26,9)
-1.84
Hist -0.17
ATR (14)
1.42
4.41% of price
Realised vol 30D
33.5%
Annualised
Bollinger upper
39.53
20, 2σ
Bollinger lower
31.39
20, 2σ
50 / 200 cross
Golden
38.89 vs 31.80
Trend bias
Above 200
+0.98%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.33
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
33.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-28.6%
Peak to trough
Max drawdown 5Y
-69.9%
Peak to trough
ATR 14
1.42
4.41% of price
Beta (reported)
0.84
5Y monthly, from filing
Short interest
Shares short
17.25M
Prior 16.98M
Change vs prior
+1.6%
Shorts adding
% of float
18.57%
Elevated
% of shares out
8.35%
Against total outstanding
Days to cover
14.6
Crowded exit
Float
91.79M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jun 30, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 26, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| May 22, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| May 21, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| May 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 15, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Feb 10, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 9, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jan 8, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Jan 6, 26 | Wolfe Research | UPGRADE | Peer Perform | Outperform |
| Dec 15, 25 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-06
Proxy Statements
DEFA14A · 2026-07-22
Periodic Financial Reports
10-K · 2026-05-20
Periodic Financial Reports
10-Q · 2026-02-06
Corporate Changes & Voting Matters
8-K · 2025-12-11
Corporate Changes & Voting Matters
8-K · 2025-11-21
Corporate Changes & Voting Matters
8-K · 2025-11-10
Headlines
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
Simply Wall St. · 7d ago
Immunovant (IMVT) Just Gave Investors Something To Think About
Simply Wall St. · 8d ago
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
MarketBeat · 9d ago
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Insider Monkey · 10d ago
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Zacks · 13d ago
Lilly’s latest China drug deal; Immunovant’s setback in lupus
BioPharma Dive · 13d ago
Roivant reports top-line data from IMVT-1402 CLE trial
Clinical Trials Arena · 13d ago
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Barrons.com · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.